探索三甲胺尿症:遗传学和分子机制,流行病学和新兴治疗策略
Antonina Sidoti1, Rosalia D'Angelo1, Andrea Castagnetti2
1Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy.
Biology
|January 8, 2025
概括
三甲基亚胺尿症 (TMAU) 是一种罕见的代谢障碍,由于三甲基亚胺的积累,引起鱼体气味. 遗传因素,如FMO3基因变异和肠道健康显著影响TMAU的发展和症状.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 微生物学 微生物学
背景情况:
- 三甲基胺尿症 (TMAU) 是一种罕见的代谢障碍,其特征是三甲基胺 (TMA) 的积累.
- 这种积累导致一种明显的鱼类般的体味,显著影响患者的生活质量.
- TMAU的发病因子是多因素的,涉及遗传倾向和环境触发因素,特别是肠道失调.
研究的目的:
- 审查关于三甲基胺氨尿症 (TMAU) 的分子基础上的当前知识.
- 澄清TMAU的诊断复杂性和治疗策略.
- 探索TMAU的新兴研究,包括遗传影响和潜在的新疗法.
主要方法:
- 关于三甲基胺氨uria (TMAU) 的现有研究的文献综述.
- 对遗传因素的分析,包括FMO3单元型和多态型.
- 检查肠道微生物群的作用及其与TMAU患者行为障碍的潜在联系.
主要成果:
- 最近的研究强调了FMO3单元型在酶活性中的作用,解释了TMAU在组合多态或异质合体变异的患者中的作用.
- 肠道疾病越来越被认为是导致TMAU的重要环境因素.
- 肠道微生物群的变化被假设与在TMAU患者中观察到的行为障碍有关.
结论:
- 转移性肺炎综合症是一种复杂的综合症,具有复杂的遗传和环境基础.
- 了解FMO3基因变异和肠道微生物群对于准确诊断和有效管理TMAU至关重要.
- 对新型治疗方法的进一步研究对于改善患者治疗结果至关重要.
相关概念视频
01:22Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
01:20Inborn Errors of Metabolism
126
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
126
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:24Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444